Evidence map›Paper›PMID 40788181›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2025

Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET-Targeted Prostate Biopsy for Prostate Cancer Diagnosis.

Jianhua Jiao, Shuaijun Ma, Peng Wu, Xiyu Song, Hongyong Cui, Jingliang Zhang, Lei Shang, Wuhe Zhang, Yi Sun, Jixue Gao and 12 more

Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Covalent FAPI Imaging-Guided Precision Surgery in Patients with Medullary Thyroid Carcinoma: A Phase II Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jianhua Jiao *Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.ORCID 0000-0003-0227-7401
Shuaijun Ma *Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.ORCID 0000-0003-3566-6913
Peng Wu *Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.ORCID 0009-0006-0949-7289
Xiyu SongNational Translational Science Center for Molecular Medicine, Department of Cell Biology, Fourth Military Medical University, Xi'an, China.ORCID 0009-0007-8543-4770
Hongyong CuiNational Translational Science Center for Molecular Medicine, Department of Cell Biology, Fourth Military Medical University, Xi'an, China.ORCID 0000-0003-0051-2666
Jingliang ZhangDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.ORCID 0000-0002-2132-3621
Lei ShangDepartment of Health Statistics, Fourth Military Medical University, Xi'an, China.ORCID 0000-0003-0470-0066
Wuhe ZhangDepartment of Urology, Xijing 986 Hospital Department, Xi'an, China.ORCID 0009-0006-4258-2952
Yi SunDepartment of Urology, Shaanxi Provincial People's Hospital, Xi'an, China.ORCID 0009-0001-5700-2950
Jixue GaoDepartment of Urology, Affiliated Hospital of Yan'an University, Yan'an, China.ORCID 0009-0004-7165-6047
Weihong ZhaoWeinan Central Hospital, Middle section of Shengli Street, Weinan City, China.ORCID 0009-0002-5965-6322
Wei ZhengDepartment of Urology, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, China.ORCID 0009-0007-8743-4547
Yuming JingDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.ORCID 0009-0005-5380-7750
Xiaojian YangDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.ORCID 0000-0002-8632-2750
Jing ZhangState Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.ORCID 0000-0001-7719-6943
Wenwen WangDepartment of Health Statistics, Fourth Military Medical University, Xi'an, China.ORCID 0000-0003-1547-5714
Qiang ZhangDivision of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.ORCID 0000-0002-6633-9547
Nianzeng XingDepartment of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0002-2696-5279
Weihong WenInstitute of Medical Research, Northwestern Polytechnical University, Xi'an, China.ORCID 0000-0003-4739-4871
Yongquan ShiState Key Laboratory of Integrative Management of GI Cancer, Department of Gastroenterology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.ORCID 0000-0001-9515-7577
Fei KangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.ORCID 0000-0003-0267-7819
Weijun QinDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.ORCID 0000-0002-7509-7164

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTransrectal ultrasound-guided prostate biopsy (TRUS-GB) is associated with the underdiagnosis of prostate cancer, and prostate-specific membrane antigen (PSMA)-PET-targeted prostate biopsy (PSMA-TB) may reduce the misclassification of prostate cancer. The primary outcome of the study was the accuracy of the two methods in identifying clinically significant prostate cancer (csPCa). The secondary outcomes included accuracy in identifying clinically insignificant prostate cancer (GG1) and GG3 or greater tumors, cancer detection stratified by the previous biopsy status, and the detection rate of csPCa using the combination of PSMA-TB and TRUS-GB. PATIENTS AND

methodsIn this multicenter, two-arm, randomized study, biopsy-naïve patients suspected of having prostate cancer and advised to undergo prostate biopsy were randomly assigned to the PSMA-TB + TRUS-GB (combined) and TRUS-GB (control) groups.

resultsA total of 815 men were assessed for eligibility, and 727 men were randomly assigned to the PSMA-TB + TRUS-GB group or the TRUS-GB group. The detection rate of csPCa in the group subjected to the combination of PSMA-TB and TRUS-GB was significantly greater than that in the conventional TRUS-GB group (67.0% vs. 60.1%; P = 0.042). In the PSMA-TB + TRUS-GB group, the rate of csPCa detection by PSMA-TB was significantly greater than that by TRUS-GB (63.5% vs. 57.7%; P < 0.001), whereas the combined strategies achieved the highest detection rate (67.0% vs. 63.5%, P < 0.001; 67.0% vs. 57.7%, P < 0.001).

conclusionsThe diagnostic efficacy of TRUS-GB with PSMA-TB was significantly greater than that of TRUS-GB alone. If available, PSMA-TB should be performed alongside TRUS-GB in a combined manner rather than each method alone for the most accurate pathologic results.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIImage-Guided BiopsyPositron-Emission TomographyProstateProstatic NeoplasmsAgedHumansMaleMiddle AgedAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase II

Identifiers

PMID40788181
PMCPMC12521911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.